about
sameAs
Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitorMulti-level targeting of the phosphatidylinositol-3-kinase pathway in non-small cell lung cancer cellsMultiorgan metastasis of human HER-2+ breast cancer in Rag2-/-;Il2rg-/- mice and treatment with PI3K inhibitorNovel phosphatidylinositol 3-kinase inhibitor NVP-BKM120 induces apoptosis in myeloma cells and shows synergistic anti-myeloma activity with dexamethasone.PAK1 mediates resistance to PI3K inhibition in lymphomas.Vertical targeting of the phosphatidylinositol-3 kinase pathway as a strategy for treating melanoma.ERα-dependent E2F transcription can mediate resistance to estrogen deprivation in human breast cancerPreclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer.Inhibiting PI3K reduces mammary tumor growth and induces hyperglycemia in a mouse model of insulin resistance and hyperinsulinemia.Efficacy of phosphatidylinositol-3 kinase inhibitors in a primary mouse model of undifferentiated pleomorphic sarcoma.NVP-BKM120, a novel PI3K inhibitor, shows synergism with a STAT3 inhibitor in human gastric cancer cells harboring KRAS mutations.Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancerAntitumor activity of NVP-BKM120--a selective pan class I PI3 kinase inhibitor showed differential forms of cell death based on p53 status of glioma cellsThe phosphatidylinositol-3 kinase I inhibitor BKM120 induces cell death in B-chronic lymphocytic leukemia cells in vitro.PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition.Targeting PI3K and mTORC2 in metastatic renal cell carcinoma: new strategies for overcoming resistance to VEGFR and mTORC1 inhibitors.Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors.The combination of RAD001 and NVP-BKM120 synergistically inhibits the growth of lung cancer in vitro and in vivo.3D tumour spheroids as a model to assess the suitability of [18F]FDG-PET as an early indicator of response to PI3K inhibition.Characterization of the mechanism of action of the pan class I PI3K inhibitor NVP-BKM120 across a broad range of concentrations.Selective PI3K inhibition by BKM120 and BEZ235 alone or in combination with chemotherapy in wild-type and mutated human gastrointestinal cancer cell lines.
P921
Q27676347-58C459D7-1945-43BF-A71D-C724404D635BQ28480805-D828891A-C441-4CE6-9657-18CBD1B46422Q28728165-A445800B-E334-4C5C-BFD5-86CE2FEB36A7Q34420112-23626460-D208-452E-BF75-F98FB7BEC51BQ34539577-D218FB50-58EC-4F45-8F2F-139D30E4CE60Q34682072-BB38FEAA-FFE3-4F6D-8247-327727D5F79DQ35479617-A0B24DC1-526D-4C28-8656-A4A81B19C0FDQ35558909-D473B85E-2977-4A39-BE88-81688D4ECB47Q35745395-6D3F621D-0F4F-445F-93FB-5675534F89F3Q35955302-538317D7-FD88-47D3-BA17-D0DDE76A0ED2Q36645788-A4303A99-3C17-4EE8-9236-0CA7FBB60548Q37069878-777CE76F-B6D6-4E9B-AAAA-4DFC40AF3CC9Q37203000-2DB266E4-ED1C-4030-9C5C-0F793B33B2DAQ37358321-BE0E74E0-6391-4C4B-8EFA-F9C51F20F57FQ37445131-2FC345E1-F90F-4172-B1A9-48FBC4CAC6AEQ38074121-9ACC7777-BA1E-4041-89F0-CBCC6733330DQ38406496-3ECD0591-9F26-4627-B092-DD5940616CC3Q39317004-460110BC-A5A9-48E8-9CED-0C26838A3017Q39334495-CA25F9C4-FFEF-4CDA-83AE-2D0A008E2E0CQ39338784-480F6766-058B-47F5-8613-D2ADCAB35E78Q43411752-2FCFDC9A-2208-4B0A-992C-23F48767E0A5
P921
description
chemesch Verbindung
@lb
chemical compound
@en
chemical compound
@en-ca
chemical compound
@en-gb
chemická sloučenina
@cs
chemická zlúčenina
@sk
chemiese verbinding
@af
chemische Verbindung
@de
chemische Verbindung
@de-ch
chemische verbinding
@nl
name
buparlisib
@en
type
label
buparlisib
@en
altLabel
BKM 120
@en
BKM-120
@en
BKM120
@en
NVP-BKM120
@en
prefLabel
buparlisib
@en
P592
P6366
P638
P661
P662
P683
P117
P1579
P2067
P2275
buparlisib
@en
P231
944396-07-0
P232
P233
C1COCCN1C2=NC(=NC(=C2)C3=CN=C(C=C3C(F)(F)F)N)N4CCOCC4
P234
1S/C18H21F3N6O2/c19-18(20,21)1 ...... 8-4-27/h9-11H,1-8H2,(H2,22,23)
P235
CWHUFRVAEUJCEF-UHFFFAOYSA-N
P2566
100.232.248
P274
C₁₈H₂₁F₃N₆O₂
P3117
DTXSID50241486
P592
CHEMBL2017974